Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Facing Pricing Pressure And Generic Erosion, Simcere Shifts To Innovative Products For Future Growth: China Earnings Roundup (Part I)

This article was originally published in PharmAsia News

Executive Summary

China’s healthcare industry saw slower growth in the third quarter. In a recurring feature, PharmAsia News combs through earnings reports to bring you highlights of China’s leading pharma companies and how their efforts affect different sectors of the industry.

You may also be interested in...



Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity

BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country

Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal

NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership

Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?

SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141439

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel